Oral Losartan in Prevention of Post-ERCP Paancreatitis
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention
of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50
patients underwent ERCP without receiving oral losartan.